186 related articles for article (PubMed ID: 20170959)
1. Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms.
Fung TK; Cheung AM; Kwong YL; Liang R; Leung AY
Leuk Res; 2010 Oct; 34(10):1390-4. PubMed ID: 20170959
[TBL] [Abstract][Full Text] [Related]
2. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice.
Ishii T; Zhao Y; Sozer S; Shi J; Zhang W; Hoffman R; Xu M
Exp Hematol; 2007 Nov; 35(11):1633-40. PubMed ID: 17764815
[TBL] [Abstract][Full Text] [Related]
3. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
[TBL] [Abstract][Full Text] [Related]
4. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
Kilpivaara O; Levine RL
Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
[TBL] [Abstract][Full Text] [Related]
5. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
6. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
Wang J; Ishii T; Zhang W; Sozer S; Dai Y; Mascarenhas J; Najfeld V; Zhao ZJ; Hoffman R; Wisch N; Xu M
Leukemia; 2009 Sep; 23(9):1577-86. PubMed ID: 19387466
[TBL] [Abstract][Full Text] [Related]
7. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
8. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
9. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
10. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
[TBL] [Abstract][Full Text] [Related]
11. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
12. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
[TBL] [Abstract][Full Text] [Related]
13. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
[TBL] [Abstract][Full Text] [Related]
14. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
[TBL] [Abstract][Full Text] [Related]
15. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
16. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.
Alvarez-Larrán A; Bellosillo B; Pereira A; Kerguelen A; Hernández-Boluda JC; Martínez-Avilés L; Fernández-Rodríguez C; Gómez M; Lombardía L; Angona A; Ancochea A; Senín A; Longarón R; Navarro B; Collado M; Besses C
Am J Hematol; 2014 May; 89(5):517-23. PubMed ID: 24458835
[TBL] [Abstract][Full Text] [Related]
17. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
[TBL] [Abstract][Full Text] [Related]
18. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alvarez-Larrán A; Angona A; Martínez-Avilés L; Bellosillo B; Besses C
Leuk Res; 2012 Mar; 36(3):324-6. PubMed ID: 22001278
[TBL] [Abstract][Full Text] [Related]
19. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.
Tefferi A; Vainchenker W
J Clin Oncol; 2011 Feb; 29(5):573-82. PubMed ID: 21220604
[TBL] [Abstract][Full Text] [Related]
20. JAK2V617F mutation and spontaneous megakaryocytic or erythroid colony formation in patients with essential thrombocythaemia (ET) or polycythaemia vera (PV).
Mustjoki S; Borze I; Lasho TL; Alitalo R; Pardanani A; Knuutila S; Juvonen E
Leuk Res; 2009 Jan; 33(1):54-9. PubMed ID: 18760472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
